BofA Downgrades Allergan to 'Neutral'

Analyst David Maris says the specialty-drug maker's stock is trading well above his $75 target

Banc of America downgraded Allergan (AGN ) to neutral from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.